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ABSTRACT  
   
 Many people with or at risk for diabetes have difficulty maintaining normal 
postprandial blood glucose levels (120-140 mg/dl). Research has shown that 
vinegar decreases postprandial glycemia. The purpose of this study was to 
examine a possible mechanism by which vinegar decreases postprandial 
glycemia, particularly the effect of vinegar ingestion on gut fermentation. 
 In this parallel arm randomized control trial, the effects of daily ingestion 
of vinegar on gut fermentation markers were observed among adults at risk for 
type 2 diabetes in Phoenix, Arizona. Subjects (n=14) were randomly assigned to 
treatments consisting of a vinegar drink (1.5g acetic acid) or a placebo (2 vinegar 
pills containing 40mg acetic acid each). All participants were required to 
consume the vinegar drink (16 oz) or 2 placebo pills every day for 12 weeks. At 
week 12, participants filled out a questionnaire to report gastrointestinal (GI) 
symptoms and three consecutive breath samples were taken from each subject 
to measure fasting breath hydrogen (BH2) with a breath analyzer.  
 Fasting BH2 measures for the vinegar drink group (16.1+11.8 ppm) were 
significantly different than those from the pill group (3.6+1.4) with a partial eta 
squared of 0.39 (p=0.023). After adjusting for age as a confounding factor 
(r=0.406) and removing an outlier, fasting BH2 measures for the vinegar drink 
group (4.3+1.1 ppm) were still significantly different than those from the pill group 
(3.6+1.4) with a partial eta squared of 0.35 (p=0.045). Participants in both groups 
reported mild changes in GI symptoms. In conclusion, adults at risk for type 2 
diabetes that consume 2 tablespoons of vinegar a day may have increased gut 
fermentation compared to those who do not consume vinegar. 
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Chapter 1 
INTRODUCTION 
Problem 
 Seventy-nine million people in the United States are believed to have 
prediabetes, a condition that precedes type 2 diabetes (1). Prediabetes is a 
condition that consists of blood glucose concentrations that are above normal 
(>100 ml/dL), but do not quite reach those of diagnosed type 2 diabetics (>126 
mg/dL) (1).  
 Type 2 diabetes is characterized by a decreased production or use of 
insulin, or both. Risk factors associated with diabetes include impaired glucose 
tolerance, hypertension, low HDL cholesterol, and high plasma triglycerides (2). 
Populations that may be at a higher risk for developing type 2 diabetes include 
older individuals, African-Americans, Latinos, Native Americans, Asian 
Americans, Native Hawaiians and other Pacific Islanders (3). Serious 
complications from diabetes include heart disease, stroke, hypertension, 
neuropathy, nephropathy, and retinopathy (4,5).  
 According to the American Diabetes Association, long-term 
cardiovascular damage is already in progress in prediabetics (1). The goal for 
treating prediabetes is to stop or slow progression so it does not advance to full-
fledged type 2 diabetes, which results in serious health complications. This can 
be accomplished with medical therapy and healthy lifestyle changes, such as 
modifying diet and exercise. Due to the increasing prevalence of prediabetes and 
diabetes, there is an increased demand for the discovery of viable methods to 
delay the onset of pre and type 2 diabetes.  
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 Studies that have addressed the increasing prevalence of diabetes have 
found that lifestyle modifications are effective to prevent, delay onset, and aid in 
the treatment of diabetes (6-8). The benefits of lifestyle modifications to prevent  
and delay the onset of chronic disease are evident, however, there remains a 
steady increase in obesity and diabetes (9).  
 Studies report that lifestyle interventions for prevention of diabetes are 
cost-effective, so cost is likely not the central problem (10-12). Perhaps trends 
are showing an increase in diabetes due to poor patient adherence to lifestyle 
modifications that are meant to reduce risk factors associated with diabetes 
(13,14). The number one barrier to controlling hypertension—a risk factor for 
diabetes—is making lifestyle changes such as eating a healthy diet and 
increasing physical activity to lose weight (15). Barriers to diet modification 
adherence include unwillingness to change dietary habits, difficulties consuming 
a diet different from family and friends, and attending social gatherings. Barriers 
to compliance with exercise recommendations included lack of time, limitations 
due to other illness or disease, and poor weather conditions (16). There is a 
constant need for preventative options that are easier for patients to implement 
and maintain. 
 Recent studies have shown that consumption of vinegar decreases 
postprandial glycemia and improves postprandial insulin sensitivity (17-20). 
Previous data also suggest that vinegar may potentially decrease blood pressure 
and hemoglobin A1C (HbA1c) values and increase satiety (19,21-23). Vinegar is 
inexpensive, has a long shelf life, and is an appealing option for prevention and 
treatment of type 2 diabetes. 
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 A few studies have explored delayed gastric emptying as a potential 
mechanism by which vinegar decreases postprandial glycemia, however, it 
appears that there remains a deficiency of studies in the literature exploring the 
glucose lowering actions of vinegar (24-26). 
Proposed Research 
 Studies have shown that vinegar decreases postprandial glycemia and 
improves risks associated with type 2 diabetes. The importance of this research 
is to better understand how this phenomenon happens. The purpose of this 
parallel arm randomized control trial is to observe the effects of daily vinegar 
ingestion before meals on fermentation markers among adults at risk for type 2 
diabetes in Phoenix, Arizona. The aim of this study is to examine a possible 
mechanism by which vinegar decreases postprandial glycemia, specifically the 
impact of vinegar ingestion on gut fermentation. This will be explored to ascertain 
whether vinegar inhibits the digestion of starch in the small intestine. It was 
hypothesized that the ingestion of 2 tablespoons of vinegar each day would have 
no effect on fermentation markers in adults at risk for type 2 diabetes in Phoenix, 
Arizona. 
Definition of Terms 
Dawn effect: A rise in blood glucose in the morning in diabetics 
Disaccharide: A simple sugar consisting of two monosaccharides.  
 E.g. sucrose, lactose, and maltose 
Disaccharidase: The digestive enzyme that breaks disaccharides down to simple 
 molecules of sugar such as monosaccharides. 
Glycosidase:  Cleaves β-linked sugar residues from glycosides 
Monosaccharide: The most basic carbohydrate unit.  
   4
 E.g. glucose, fructose, and galactose 
Polysaccharide depolymerase: An enzyme that breaks down polysaccharides to 
 simpler molecules, such as disaccharides and monosaccharides. 
Postprandial glycemia: A rise in blood glucose after eating 
Prediabetes: Individuals with a fasting blood glucose of 100-125mg/dL 
Delimitations and Limitations 
 Subjects are adults from Phoenix, Arizona who are at risk for type 2 
diabetes and have been told by their doctor that they have prediabetes. 
Therefore the findings of this study cannot generalize beyond this population 
group. Fermentation markers were measured using a hydrogen breath test. Any 
self-reported data may not be accurately recorded, and there is no guarantee 
that subjects are maintaining their exercise and eating habits for the duration of 
the study. There is also no guarantee that subjects will consume the vinegar pill 
or drink each day during the 12-week trial as requested.   
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Chapter 2 
LITERATURE REVIEW 
Vinegar Overview 
 
Production 
 Vinegar is derived from the Latin based word “vinaigre,” which means 
eager wine. The word eager comes from the French word “aigre,” meaning sour 
or sharp. Therefore, vinegar literally means sour or sharp wine (27).  
 Vinegars that are widely used in commercially prepared and homemade 
foods are produced by enzymatic fermentation of carbohydrate sources, such as 
fruit and grain, to alcohol. Yeast, namely Saccharomyces cerevisiae, is primarily 
responsible for the conversion of sugars to alcohol (27). Microorganisms called 
acetic acid bacteria are involved in the transformation of alcohol to acetic acid 
through oxidation. Acetobacter, a form of acetic acid bacteria, combines with 
oxygen to oxidize alcohol to acetic acid (vinegar) and water. This process is 
represented in the following equation: 
 Step 1: Conversion of sugar to alcohol 
 Glucose           Yeast            Ethanol 
 C6H12O6 2(CH3CH2OH)   +   2(CO2)        
  
 Step 2: Fermentation of alcohol to acetic acid 
      Ethanol    Acetobacter     Acetic Acid (Vinegar) 
 CH3CH2OH   +   O2                 CH3COOH    +    H20  
 To complete this process, vinegar manufacturers require phage resistant 
acetic acid bacteria that can withstand high acetate concentrations, have high 
production rates, require minimal nutrients for growth, and do not overoxidize the 
acetic acid they produce. Overoxidation occurs when there is a lack of ethanol, 
which causes acetic acid to be further oxidized to CO2 and H2O (28).  
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 Commercial vinegar can be made by fast or slow fermentation. Fast 
fermentation methods, also known as submerged vinegar fermentation, require 
rapid mixing. In this process, the acetic acid bacteria dwell under the surface, 
allowing for quick fermentation of sugar-containing liquids. When desired acetic 
acid concentrations are reached, vinegar is released from the fermenter and 
replaced with alcohol-rich liquid to create more vinegar product (28). The slow 
fermentation process, also known as surface fermentation, is used to make 
traditional wine vinegars and is said to produce the best flavor (28, 29). In this 
method, acetic acid bacteria remains on the liquid’s surface, resulting in a slower 
fermentation process that can last weeks, sometimes months. Extended periods 
of fermentation allow for the growth of a nontoxic slime composed of yeast and 
acetic acid bacteria. This substance is known as mother of vinegar (29). Vinegar 
is filtered and pasteurized before bottling in order to prevent the formation and 
growth of these organisms (28, 29).  
. The final product of the vinegar production process is composed of acetic 
acid, ethanol, vitamins, inorganic salts, amino acids, polyphenols, and organic 
acids (29, 28). While acetic acid is a key component of vinegar, it only accounts 
for 4% of the final product. Federal regulation defines vinegar as the product 
made by alcoholic fermentation of sugar, containing no less than 4 grams of 
acetic acid per 100 cubic centimeters (27).  Although vinegar is only required to 
contain 4% acetic acid, typically white vinegars contain 4% to 7% acetic acid and 
cider and wine vinegars contain 5% to 6% acetic acid (29).  
 Vinegars can be classified as herbal or fruit vinegar depending on what 
ingredients are added to wine vinegars or white distilled vinegars. Herbs and 
spices such as basil, cinnamon, clove, garlic, nutmeg and tarragon can be added 
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to make herbal vinegars. Fruit or fruit juice may be added to vinegar to produce 
fruit vinegars. These vinegars typically generate a sweet-sour taste. The sour 
taste for fruit vinegars can be attributed to the acetic acid, while the fruit juices 
are responsible for its sweetness. Vinegars may also be classified as traditional 
vinegar, depending on where and how they are produced (29). For example, 
balsamic vinegar from Modena, Italy is made from Trebbiano grape juices. It is 
fermented in a series of barrels made from various woods. This process can take 
anywhere from 3 to 12 years.  Traditional vinegars also include rice wine and 
coconut vinegars from Asia, cane vinegar from the Philippines, and raisin vinegar 
from the Middle East (27). Vinegar has had many uses throughout history, 
especially within the fields of the culinary arts, agriculture, and medicine. 
History of Use 
 Medicinal use of vinegar can be traced back to the time of ‘the father of 
modern medicine,’ or Hippocrates (460-370 BC), when it was used as a means 
of fighting infection and treating other acute conditions. Hippocrates suggested 
the use of vinegar to clean and treat wounds and sores. He also recommended 
honey and vinegar for the treatment of persistent coughs, as many physicians 
still advise today. This medicine was called oxymel, and is a mixture of virgin 
honey and white wine vinegar 4 parts to 1 (29, 30).  
 Many others followed after Hippocrates, using vinegar to treat various 
conditions. Paulus Aegineta (607-690 AD), a Greek physician, used vinegar as 
an astringent and as a treatment for wounds (30). In the 10th century, Sung Tse, 
the founder of forensic medicine, professed that infection from autopsies could 
be avoided by washing the hands with a sulfur and vinegar solution (29).  
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 Legend purports that vinegar was used in the Middle Ages (1348-1350 
AD), to prevent infection from the black plague. Four thieves who robbed the 
homes of French plague victims and never contracted the black plague 
themselves were put on trial. They claimed they had used a concoction of garlic 
and vinegar to ward off infection in the presence of the plague victims. Following 
this incident, vinegar from this region of France became known as “le vinaigre de 
Quatre Voleurs” or four thieves vinegar, and was used to prevent infection from 
the bubonic plague (31).  
Vinegar as a Medicinal Agent 
Infectious Disease 
 Historically, vinegar was believed to prevent infection. Medical 
professionals have used it to treat numerous illnesses including dropsy, croup, 
cough, fever, wounds, burns, ulcers, and the common cold (29,32). Vinegar is 
commonly used for household cleaning purposes, however, research shows that 
chemical products are more effective disinfectants and should be used in place 
of vinegar (29,33). 
 Evidence clearly shows that vinegar is a successful antimicrobial agent in 
food preparation settings, however, its use as an antimicrobial agent for the 
treatment of wounds is not recommended (34-37). The use of vinegar to prevent 
bacterial growth in wound care has been ineffective. It has not been shown to 
prevent the growth of Escherichia coli, Exterococcus, or bacteroides fragilis, and 
its ability to inhibit growth of Staphylococcus aureus and Pseudomonas 
aeruginosa has only been found mildly effective (37).  
 Although it is not the most effective antimicrobial treatment, vinegar has 
shown beneficial effects in the treatment of ear infections and jellyfish stings. 
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Research shows that diluted vinegar solutions (2% acetic acid) with a low acidity 
(a pH of 2) may effectively treat ear infections such as otitis media and granular 
myringitis. However, vinegar concentrations with this level of acidity may damage 
cochlear hair cells and irritate the skin (29,38,39). Therefore, in the treatment of 
ear infections, antibiotics are preferred to acetic acid solutions (39). Vinegar is 
commonly used to treat acute jellyfish stings because it deactivates venom-filled 
nematocysts. However, immersing an acute jellyfish sting in hot water (40°C) is 
the most effective treatment for jellyfish stings because heat quickly deactivates 
the venom (40,41).  
 Contrary to popular belief, vinegar is not an effective treatment for head 
lice, as shown in scientific research. Compared to five other home-remedies for 
head lice, vinegar was the least successful treatment to kill lice and prevent the 
laying and hatching of eggs. Stronger chemicals are recommended for proper 
louse removal (42).  
Chronic Disease 
Cardiovascular Health 
 Many studies show that vinegar may have benefit those at risk for 
cardiovascular health. In a follow-up of the Nurses’ Health Study, food frequency 
questionnaires completed by 76,283 women in 1984 were reviewed to examine 
associations between fatal ischemic heart disease and consumption of foods 
containing alpha-linolenic acid. Investigators found that women who consumed 
oil and vinegar dressing more than 5 times a week had a 54% reduction in risk 
for fatal ischemic heart disease compared to those who did not consume oil and 
vinegar dressing (95% CI: 0.27-0.76 p for trend=0.001). The authors of this study 
speculated that the effects of the dressing could be attributed to its alpha-
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linolenic acid content. However, these benefits were not seen with the 
consumption of mayonnaise, which is also high in alpha-linolenic acid. This 
suggests that the fatal ischemic heart disease risk reduction seen with the 
consumption of oil and vinegar dressing might be attributable to other potentially 
beneficial nutrients, such as acetic acid contained in the vinegar (43).  
 A 5-week study on male Sprague-Dawley rats explored the relationship 
between acetic acid and blood lipid concentrations. Rats were put on diets that 
were either cholesterol-free, cholesterol, or cholesterol plus acetic acid. The rats 
given acetic acid had significantly lower serum cholesterol concentrations in 
comparison to both the cholesterol and cholesterol-free groups (p<0.05). They 
also showed lower triglyceride concentrations compared to the cholesterol free 
group (p<0.05). This study suggests that acetic acid may lower cholesterol and 
triglyceride concentrations (44).  
 A 12-week study in 155 obese Japanese men and women explored the 
effects of vinegar on blood lipids. Subjects were randomly assigned to drink a 
500ml daily beverage containing either 15ml vinegar (750 mg acetic acid), 30ml 
of vinegar (1,500 mg acetic acid), or 0ml vinegar (placebo). Subjects who 
consumed vinegar had significantly lower triglyceride concentrations compared to 
baseline (p<0.001) and the placebo group (p<0.05). No significant effect was 
observed in total, LDL, or HDL cholesterol values. This study also suggests that 
vinegar may have a triglyceride lowering effect (45).  
 In addition to affecting cholesterol and triglyceride levels, vinegar may 
improve cardiovascular health by lowering blood pressure. A study in non-
hypertensive male Sprague-Dawley rats explored the effects of acetic acid 
consumption on blood pressure. Rats were given a red wine vinegar and grape 
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juice beverage containing 0.57mmol of acetic acid a day, distilled water, or 
temocapril hydrochloride, an angiotensin I-converting enzyme (ACE) inhibitor. No 
significant differences were seen in baseline values between groups. After 
treatment, a significant decrease in angiotensin I-induced pressor response was 
observed among the temocapril and vinegar beverage groups at 10 minutes 
(p<0.01) and 60 minutes (p<0.05). No effects were seen in the distilled water 
group (46). This study suggests that vinegar may have hypotensive effects, 
however, the vinegar beverage used in this study also contained polyphenol 
antioxidants, which have been shown to have a beneficial effect on blood 
pressure themselves (46,47).  
 The effects of long-term vinegar consumption on blood pressure were 
studied in spontaneously hypertensive rats. Rats were put on a diet with 
deionized water (control), vinegar, or an acetic acid solution for 6 weeks. The 
vinegar and acetic acid treatments provided 0.86 mmol acetic acid each day. 
Systolic blood pressure was significantly reduced in the acetic acid and vinegar 
groups (20 mm Hg) compared to the control (p<0.05). The vinegar and acetic 
acid groups also showed significant reductions in plasma rennin activity (35% to 
40%) and plasma aldosterone concentrations (15% to 25%) compared to the 
control group (p<0.05). This suggests that reduced rennin activity and 
aldosterone concentrations may be responsible for the observed reduction in 
systolic blood pressure. This study suggests that acetic acid is largely 
responsible for the antihypertensive actions of vinegar (48). More research is 
required in addition to these studies to further understand the effects of vinegar 
consumption on cholesterol and blood pressure in humans. 
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Dietary Control 
 In addition to cardiovascular benefits, research indicates that vinegar 
consumption may aid in weight management (19,45). A 12-week study in 155 
obese Japanese men and women explored the effects of vinegar on body weight 
and fat mass. Subjects were randomly assigned to drink a 500ml daily beverage 
containing 0ml vinegar (placebo), 15ml vinegar (750 mg acetic acid), or 30ml of 
vinegar (1,500 mg acetic acid). Subjects who consumed vinegar had significantly 
lower body weight, BMI, visceral fat area, and waist circumference measures 
compared to baseline and the placebo group (p<0.001). This study suggests that 
vinegar may aid in weight management, which could reduce obesity and help 
prevent the onset of chronic disease, such as metabolic syndrome, 
cardiovascular disease, and diabetes (45).  
 Östman and colleagues suggest that vinegar may aid in weight 
management by increasing satiety. Twelve healthy volunteers were randomly 
assigned to consume 0, 18, 23, or 28g of vinegar (6% acetic acid) with white 
bread following an overnight fast. Subjects consumed each of the four meals on 
separate occasions, one week apart. Satiety was measured with a rating scale. 
Following the 28g vinegar treatment, subjects experienced significantly greater 
satiation for a longer period of time compared to the control group (p<0.05). They 
also showed a 22% decrease in glycemic index of the test meal (19). Other 
research has shown that consumption of lower glycemic index foods is 
connected to decreased hunger cues compared to foods with a higher glycemic 
index (49). Vinegar studies have shown an inverse relationship between vinegar 
and glycemic index. This study suggests that vinegar plays a role in appetite 
regulation by lowering the glycemic index of foods (19). 
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Vinegar and Diabetes  
Glycemic Control 
 Diabetics generally have poor glycemic control. Studies have shown that 
consumption of low glycemic index foods aid in the prevention of type 2 diabetes 
(50,51). The glycemia of a carbohydrate food can be altered by ingestion of 
foods that decrease the delivery rate of glucose into the bloodstream (52). Many 
studies that have explored vinegar consumption and glycemia show that vinegar 
can lower postprandial glycemia to help delay the onset of type 2 diabetes and 
aid in treatment once diagnosed. In fact, many diabetics consumed vinegar tea to 
aid in the management of diabetes before the development of hypoglycemic 
agents (29).  
 In 1988, Ebihara and Nakajima were among the first to discover the 
antiglycemic effect of vinegar and suggest its use to treat type 2 diabetes. In their 
study, rats given 7% vinegar solution for 10 weeks had significantly lower 
postprandial blood glucose concentrations (53). In 1995, Brighenti and 
colleagues examined this effect in humans. In a randomized crossover trial, they 
assigned 5 healthy subjects to consume lettuce dressed with 10g olive oil 
(control), 10g olive oil and 20ml vinegar (5% acetic acid), or 10g olive oil and 20 
ml neutralized vinegar (sodium acetate, pH=6.0) in random order on three 
separate occasions. Meals were followed by a glucose challenge test 
immediately after each treatment, using white bread (50g carbohydrate) as a 
reference. Blood glucose was reduced 31.4% (p=0.02) over 95 minutes after 
consumption of acetic acid compared to other groups. This suggests that vinegar 
containing acetic acid significantly improved glycemic responses to a mixed meal 
in healthy subjects (24).  
   14 
 Östman and colleagues conducted a study in 2005, to explore whether 
acetic acid supplementation could lower the glycemic index of a meal consisting 
of bread. They measured postprandial glucose and insulin concentrations in 12 
healthy subjects after consumption of 50g of white bread with 0, 18, 23, and 28 g 
of white vinegar containing 6% acetic acid. After an overnight fast, subjects 
underwent each vinegar treatment in random order, on four separate days with a 
1-week washout period between treatments. There was a negative linear 
relationship between 30-minute postprandial blood glucose concentrations and 
the amount of vinegar consumed with the test meal (r=-0.47, p=0.001). There 
was also a negative linear relationship between 30-minute insulin responses and 
vinegar content of the test meal (r=-0.44, p=0.002). The glycemic index of the 
test meal decreased 22% in the group that consumed 28g of vinegar and white 
bread compared to the group that consumed white bread alone (p<0.05). This 
study suggests that vinegar may lower the glycemic index of bread and decrease 
postprandial glycemia and insulinemia (19). 
 White and Johnston studied the influence of vinegar ingestion at bedtime 
on the dawn effect. In a randomized crossover trial, 11 type 2 diabetics followed 
the same 2-day meal plan consuming either 2 tbsp of apple cider vinegar or 
water (placebo) at bedtime. Participants measured their fasting blood glucose at 
7:00am each morning with a glucometer and underwent a 3-5 day washout 
period between treatments. Fasting glucose concentrations were reduced 2% 
(0.15mmol/l) in the placebo group and 4% (0.26mmol/l) in the vinegar group 
(p=0.033). The results of this study suggest that vinegar consumption before 
bedtime may have a favorable impact on the dawn effect in type 2 diabetics (54).  
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 In 2009, Johnston and colleagues showed that vinegar ingestion 
improved glycemic control in individuals with type 2 diabetes. Twenty-four 
healthy subjects were randomly assigned to consume a vinegar pill (15mg acetic 
acid), a pickle (700mg acetic acid) or 2 tbsp of vinegar (1400mg acetic acid) 
twice a day for 12 weeks. The vinegar pill served as the control because 15mg of 
acetic acid is so miniscule it is without effects. Fasting blood samples were taken 
at weeks 0, 6, and 12. HbA1c decreased 0.16% in the vinegar group over the 12 
weeks while values increased in the vinegar pill and pickle groups (p=0.018). The 
observed decrease in HbA1c in the vinegar group indicates an improvement in 
glycemic control with the ingestion of 2 tbsp of vinegar a day (23). 
 Johnston and colleagues explored the effectiveness of various vinegar 
doses (10g or 20g), ingestion times (during meal or 5h before meal), forms 
(acetic acid from vinegar or sodium acetate), and carbohydrate sources 
(dextrose or complex carbohydrate) on the reduction of postprandial glycemia in 
a series of four randomized crossover trials. All trials consisted of a standardized 
meal the night before testing, an overnight fast, and a 2-hour glucose test after 
consumption of either a dextrose solution or a bagel and juice meal. Postprandial 
glucose concentrations were compared between treatments for up to 120 
minutes post meal. All treatments within each trial were separated by a 1-week 
wash-out period. Results showed that 10g of vinegar (5% acetic acid) decreased 
postprandial glycemia by 23-28% (p=0.05) compared to the placebo whereas the 
20g vinegar dose only dereased postprandial glycemia by 6-12% compared to 
the placebo group. Vinegar ingestion at the same time as the test meal 
decreased postprandial glycemia by 19% (p=0.169) but had no impact on 
postprandial glycemia when ingested 5 hours before the test meal. Postprandial 
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glycemia was reduced 90% more with ingestion of vinegar with a bagel 
compared to vinegar ingested with a dextrose drink (p=0.059). Acetic acid from 
vinegar decreased postprandial glycemia by 13-17% compared to the sodium 
acetate and placebo treatments (p=0.097). This study suggests that 10g of a 5% 
acetic acid vinegar solution, ingested with complex carbohydrates, will decrease 
postprandial glycemia in healthy individuals (20). 
 Similar effects of vinegar on glucose and insulin responses were also 
seen in other studies (55, 18, 17, 22). The evidence shows that vinegar has a 
beneficial effect on glycemia. The next step in research is to understand what 
causes the antiglycemic effect of vinegar. There are many possible mechanisms 
that may explain this phenomenon. Potential mechanisms explored in current 
research include delayed gastric emptying, inactivation of digestive enzymes, 
and enhanced tissue uptake.  
Glycemic Control Mechanisms 
  
Delayed Gastric Emptying 
 
 The idea that acids can slow gastric emptying rates has been around 
since the late 1800’s. Results were mainly shown using hydrochloric acid. In 
1972, Hunt and Knox studied the effects of 9 different acids (hydrochloric, acetic, 
lactic, tartaric, phosphoric, citric, propionic, butyric, and hexanoic) on gastric 
emptying rates in 20 healthy subjects. They found that acids with lower molecular 
weights had more potential to delay gastric emptying than those with higher 
molecular weights. Since acetic acid (60g/mol) has a lower molecular weight than 
the other acids in this study, it should be the most effective in slowing gastric 
emptying rates (56).  
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 Gastric emptying rates can be determined by measuring antrum diameter. 
Pressure in the antrum, the area just inside the pylorus of the stomach, builds 
from peristaltic contraction. High pressures in the antrum lead to more rapid 
gastric emptying (57). Food consumption stimulates chemosensitive receptors, 
which lead to a decrease in antral pressure and pyloric contraction, thus slowing 
gastric emptying. By measuring the diameter of the antrum, this pressure can be 
measured to determine gastric emptying rates (58).  
 In the 1995 study by Brighenti and colleagues that was previously 
outlined in this text, no effect of various vinegar treatments was seen on gastric 
emptying rates. Gastric emptying was determined in 5 healthy subjects by gastric 
antrum diameter measures attained by real time ultrasonography (24). Brighenti 
and colleagues measured antrum diameter just prior to each meal and every 15 
minutes post-meal until values fell back to baseline. No differences in gastric 
emptying rates were observed after the white vinegar (5% acetic acid) and 
neutralized vinegar (sodium acetate with a pH of 6.0) treatments, suggesting that 
vinegar is working to decrease glycemia by some other mechanism (24). 
 In 1998 Liljeberg and Björck examined the effects of acetic acid (in the 
form of vinegar) on gastric emptying rates. They used paracetamol, an over-the-
counter pain reliever and fever reducer, as an indirect marker for gastric 
emptying. They incorporated paracetamol (1.0g per test meal) into the white 
bread. Ten healthy subjects were served two test meals after an overnight fast 
on separate days, in random order, with 1 week between tests. The reference 
meal consisted of 122g white bread (50g starch) dipped in 8g olive oil and was 
eaten with 23g cheese (providing 10% fat). The test meal consisted of the 
reference meal plus 20g white vinegar to dip the bread in. Capillary blood 
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samples were taken at 0, 15, 30, 45, 70, and 95 minutes post meal to measure 
paracetamol concentrations using an enzyme kit. Postprandial glucose, insulin, 
and paracetamol responses were significantly lower in the test meal compared to 
the reference meal (p<0.05). The area under the curve for paracetamol was 
approximately 20% lower for the test meal compared to the reference meal 
(p<0.05). This study suggests that vinegar decreases postprandial glucose and 
insulin responses by delaying gastric emptying in healthy individuals (59). 
 Research indicates that vinegar ingestion prior to a meal has a beneficial 
effect on gastric emptying rates. However, the studies that show these results 
measured blood paracetamol concentrations as an indirect marker for gastric 
emptying. Concentrations of paracetamol in the blood can be altered by other 
factors such as food components and gastrointestinal events, so these results 
should be carefully considered (29). In addition, hormones such as 
cholecystokinin (CCK), amylin, and glucagon-like peptide-1 (GLP-1), also 
influence gastric emptying rates. Therefore, it is possible that vinegar or other 
food components are acting on one of these hormones to influence gastric 
emptying (60-62). While reduced gastric emptying rates may help explain how 
vinegar decreases postprandial glycemia, other mechanisms may be driving this 
response. 
Digestive Enzyme Inactivation 
 
 In addition to studying the effects of vinegar on gastric emptying rates, 
scientists have also researched the influence of vinegar on digestive enzyme 
activation. Salivary amylase and pancreatic enzymes initiate carbohydrate 
digestion. Once carbohydrates are broken down, disaccharides are hydrolyzed 
by enzymes in the intestinal brush border, and monosaccharides are absorbed 
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through sugar transport systems. Research shows that vinegar may interfere with 
disaccharidase activity to decrease postprandial glycemia (63).  
 Ogawa and colleagues found that acetic acid suppresses disaccharidase 
activity, but has no effect on glucose transport in vitro. Caco-2 cells (human 
colonic carcinoma cells) were used in this study because they resemble human 
intestinal epithelial cells. They serve as a good model to study the physiological 
function of the small intestine because they express glucose transporters and 
disaccharidases similar to human small intestinal cells. Caco-2 cells were 
cultured on media containing either no acetic acid (control), or various amounts 
of acetic acid for 15 days. When exposed to up to  2.5 mmol/L of actic acid, there 
was no significant increase in glucose uptake. However, when cells were 
exposed to 5 mmol/L acetic acid, sucrase activity was suppressed to 43% of the 
control, maltose activity to 39% of the control, and trehalase and lactase activity 
to less than 8% of the control (p<0.01). Supression of disaccharidase activity was 
seen with acetic acid but not with other organic acids (citric, succinic, Ļ-maric, Ļ-
lactic, Ļ-tartaric, and itoconic acids). This study suggests that acetic acid 
(vinegar) decreases disaccharidase activity in vitro (63).  
 In 2010, Johnston and colleagues found similar results in humans. 
Postprandial glycemia was decreased when vinegar was ingested with complex 
carbohydrates, but not when ingested with monosaccharides. Two test meals 
were administered one week apart, on separate occasions to 10 healthy adults. 
The test meals consisted of 75g of dextrose consumed with vinegar drink 
containing 40g water, 1tsp saccharine, and 20g vinegar (1g acetic acid) or 
placebo drink containing 40g water and 1tsp saccharine alone (0g acetic acid). 
Results were not significant; however mean postprandial glycemia was 90% 
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greater after the vinegar treatment compared to the placebo treatment (p=0.059). 
This suggests that vinegar only lowers postprandial glycemia when ingested with 
complex carbohydrates, but has no effect when ingested with simple 
carbohydrates (20). 
 Since disaccharidase activity was suppressed in the presence of vinegar, 
it is possible that vinegar decreases postprandial glycemia by interfering with the 
catabolism of disaccharides to monosaccharides, such as glucose. If there is less 
glucose in the intestinal lumen, then less glucose will be absorbed into the 
bloodstream through sugar transport systems, which will result in decreased 
postprandial glycemia (63).  
Enhanced Tissue Uptake 
 In addition to gastric emptying rates and digestive enzyme inactivation, 
scientists have explored the effects of acetic acid on enhanced tissue uptake. 
Historically, athletes consumed pickle juice after physical activity (65). It is 
possible that this practice also contributes to repletion of glycogen stores. 
Research has shows that acetic acid activates gluconeogenesis and 
glycogenesis in rats (65-67).  
 After acetic acid is absorbed and taken up into the liver and tissues, it 
feeds into the Krebs cycle as acetyl-CoA and is metabolized to create ATP 
energy. When this happens, glucose is spared and stored as glycogen. Fushimi 
and colleagues explored the influence of acetic acid on glycogenesis in the liver 
of male Sprague-Dawley rats. The rats were randomized to receive the AIN-76  
diet (69) with the replacement of sucrose with glucose and 0 (control), 4, 8, or 
16g of acetic acid. Glycogen concentrations were determined by measures of 
glucose-6-phosphate and fructose-1,6-phosphate in the liver and muscles. 
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Concentrations of fructose-1,6-biphosphate, a substrate in glycolysis, were 
measured to determine the effect of vinegar consumption on glycolysis. Citrate 
concentrations were also measured as increased levels of citrate have been 
shown to inhibit the activity of phosphofructokinase, a rate-limiting enzyme in 
glycolysis, in vitro. The authors of this study hypothesized that acetic acid may 
increase levels of citrate, which would lead to decreased phosphofructokinase 
activity, cause a downregulation of glycolysis, and ultimately spare glucose  6-
phosphate for glycogen synthesis. Glycogen concentrations from this study were 
approximately 60% higher in the soleus muscle of the groups fed acetic acid 
compared to the control (p<0.05). Concentrations of citrate and fructose 6-
phosphate were elevated >1.3 fold in the groups fed acetic acid (p<0.1) These 
results suggest that as acetic acid is metabolized in the Krebs cycle, negative 
feedback causes glucose (from glycolysis) to be spared and stored as glycogen 
in the muscle and liver (65).  
 Similar results were seen in a study that examined glycogen repletion in 
male Wistar rats following exhaustive exercise. After an overnight fast, one group 
of rats was sacrificed and measured for baseline glycogen stores. In the 
remaining rats, glycogen stores were depleted by exhaustive swimming and rats 
were randomized to receive water, glucose, acetic acid, acetic acid and glucose, 
citric acid, or citric acid and glucose treatment immediately following exhaustion. 
Two hours after treatment, rats were sacrificed and glycogen was measured in 
liver and muscle tissues. Results showed that glycogen stores were significantly 
higher in those treated with acetic acid and glucose compared baseline (p<0.05) 
(66). 
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 Another study was conducted in 2002 that examined the effects of acetic 
acid on glycogen repletion after exercise in male Sprague-Dawley rats. 
Immediately following 2 hours of exhaustive swimming exercises, rats were 
randomized to be sacrificed or receive glucose or glucose with acetic acid. Rats 
were sacrificed 2 hours after feeding and muscle and liver glycogen stores were 
measured. Glycogen stores were significantly depleted after extreme exercise 
and were increased in all tissues 2 hours after both glucose and acetic acid 
treatments. However, muscle glycogen was significantly higher in the acetic acid 
group compared to the glucose group (p<0.05). This suggests that consumption 
of glucose with acetic acid following exercise may accelerate glycogen repletion 
in muscle more than glucose alone (67). 
 Studies in rats have shown potential for acetic acid to enhance uptake of 
glucose into muscle tissues, however more research is needed to understand 
this more clearly. Also, these results are from animal studies alone; no studies 
have explored these effects in humans.  
 Many studies have shown that vinegar has a beneficial influence on 
glycemia, but the exact mechanisms by which this happens remain unclear. 
Researchers have explored several options, many of which have yielded 
promising results. However, additional studies are required to more completely 
understand the physiological mechanisms driving the antiglycemic effect of 
vinegar. For example, fermentation is a possible mechanism that has not been 
explored in the research. 
Colonic Fermentation 
 Food that is not digested in the stomach or the small intestine passes into 
the large intestine, through the caecum, into the colon, where it is fermented by 
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the microflora in the colon. In healthy individuals, approximately 1.5kg of material 
passes through the colon each day. Here, microorganisms break down material 
that has not been degraded in previous parts of the digestive system (69).  
 A healthy colon contains over 400 species of anaerobic bacteria that are 
either directly or indirectly involved in human metabolism. Colonic bacteria are 
responsible for the fermentation and degradation of complex carbohydrates, 
proteins, peptides, amino acids, hydrogen, lactate, succinate, and ethanol. The 
major species of colonic bacteria responsible for the breakdown of complex 
carbohydrates, or polysaccharides, are gram-negative anaerobes, including 
bacteriosides, bifidobacteria, and ruminococci. These bacteria produce 
polysaccharide depolymerases and glycosidases that degrade polysaccharides. 
The growth of these bacteria in the colon is largely dependent upon the amount 
of fermentable carbohydrates available (69). Polysaccharide degrading colonic 
bacteria ferment sugar and water to produce hydrogen gas, carbon dioxide gas, 
ATP energy, and short-chain fatty acids (SCFAs). The SCFAs produced in this 
process are acetate, propionate, and butyrate (70). This process is represented 
in the equation shown below: 
 
 Carbohydrate fermentation is most prevalent in the ascending colon. 
Bacterial growth rates are highest in this portion of the colon since food 
substrates for bacterial fermentation are more prevalent. This increase in 
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carbohydrate fermentation leads to higher SCFA production (127mmol/L) in this 
region. The ascending colon has the lowest pH (5.4 to 5.9) found in the large 
intestine, which accommodates the growth of the bacteria in this region (69).  
  As material moves through the transverse colon, bacterial activity is 
reduced, resulting in decreased fermentation and reduced SCFA production (117 
mmol/L). The environment in this part of the colon is more basic (pH = 6.2) 
compared to the ascending colon (69).  
 Materials proceed to the descending colon where the most basic 
environment in the entire colon is found (pH = 6.6-6.9). Little carbohydrate 
fermentation takes place in this region since bacteria do not thrive in this 
environment. The lack of carbohydrate fermentation in this area results in the 
lowest rate of SCFA production (90 mmol/L) in the colon. However, protein 
fermentation flourishes in this section of the colon and produces materials such 
as phenols, indoles, and ammonia. Once materials leave this region, they are 
excreted from the body through the rectum as fecal matter (69). 
Fermentation of Undigested Carbohydrates 
 Individuals who are lactase-deficient or have carbohydrate maldigestion, 
have decreased catabolism of carbohydrates in the stomach and small 
intestines. As a result, more carbohydrate sources pass into the colon where 
they are broken down by fermentation. Increased colonic fermentation results in 
increased production of hydrogen gas, which diffuses into the blood and is 
exchanged into the breath where it is excreted (71). This causes higher breath 
hydrogen concentrations in these individuals. 
 In one study, nine healthy lactase-deficient individuals showed at least a 
20ppm rise in breath hydrogen after the ingestion of 20g of lactose, indicating a 
   25 
significant increase in colonic fermentation. The mean increase in peak breath 
hydrogen concentrations was 40ppm among the participants in this study. Eighty-
eight percent of these individuals reported diarrhea, excessive flatulence, and 
abdominal discomfort after milk consumption (72). These symptoms are 
associated with colonic fermentation, as fermentation produces gas and 
increases peristaltic contractions (73). This reaffirms the notion that undigested 
carbohydrates that pass into the colon are degraded by fermentation.  
 In another study, 15 healthy individuals with lactose maldigestion showed 
at least a 10ppm rise in breath hydrogen after the ingestion of milk containing 
20g of lactose. Breath hydrogen concentrations rose approximately 49ppm in 
lactose-intolerant individuals after the consumption of 20g lactose in the form of 
milk. These individuals also reported increased flatulence following ingestion of 
milk containing 20g lactose (74).  
 In 2006, Brighenti and colleagues measured breath hydrogen as a marker 
of fermentation in those consuming meals containing various amounts of 
indigestible carbohydrates. In a crossover trial, 10 healthy volunteers were given 
test meals for breakfast on 3 separate occasions, in random order. The meals 
consisted of a low glycemic index (LGI) meal, high glycemic index (HGI) meal, 
and a high glycemic index meal plus lactulose (HGI-lac). Lactulose is a highly 
fermentable and indigestible disaccharide; therefore it should increase hydrogen 
excretion. Subjects were served a uniform lunch. Breath hydrogen was 
measured immediately after each test meal and at 1-hour intervals for 10 hours 
thereafter. There was no peak in breath hydrogen in the HGI meal, however the 
LGI meal showed a significant increase in breath hydrogen measures 6 hours 
post-ingestion and remained high throughout the following 4 hours (p<0.001). 
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The same effect that was seen with the LGI meal was seen with the HGI-lac 
meal, however hydrogen measures were significantly higher in this group 
compared to both the LGI and HGI meals (p<0.001). The average peak breath 
hydrogen concentration was 18ppm after the LGI test meal and 26ppm after the 
HGI-lac test meal. This suggests that colonic fermentation increases with an 
increased supply of indigestible carbohydrate sources (75). 
 Nilsson and colleagues conducted a study exploring indigestible 
carbohydrate content of cereal foods (wheat, rye, oat, and barley) and their ability 
to influence glycemia. They measured breath hydrogen to determine 
fermentation of these foods in the colon, and blood glucose to monitor glycemia. 
They found a negative correlation between postprandial breath hydrogen and 
blood glucose concentrations at lunch (r=-0.33 p<0.05) and dinner (r=-0.22 
p<0.05). Compared to white bread, consumption of barley kernels resulted in the 
highest breath hydrogen concentrations (17.2+2.6ppm and 41.0+5.1ppm 
respectively p<0.001) and lowest blood glucose area under the curve 
(698.5+70.7mmol/L and 485.5+40.1 respectively <0.05). This is likely because 
barley kernels have the highest content of dietary fiber among the cereal foods 
tested, and fiber consumption contributes to colonic fermentation (76). 
 These studies show that as indigestible carbohydrate sources pass into 
the colon, colonic fermentation increases. This results in an increased production 
of hydrogen gas, a byproduct of fermentation, which diffuses into the blood, and 
is excreted in the breath (75). 
Colonic Health 
 Colonic microorganisms pose many benefits to human health. Growth of 
colonic microflora can be affected by factors such as diet, stress, infection, 
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medication, ageing, and genetics (77). Bacteria in the colon are responsible for 
fermentation of dietary fibers and other fermentable sources, producing 
metabolites, such as SCFAs, that are beneficial to colonic health (78). One of the 
most studied colonic bacteria is bifidobacteria. Increased levels of this bacterium 
have been associated with increased immune function and reduced risk for colon 
cancer and gastrointestinal disease due to improved bowel function. These 
benefits are likely caused by a decrease in inflammation. Studies have shown 
that acetic acid is associated with decreased markers of inflammation, such as 
tumor necrosis factor (TNF-α) and other inflammatory cytokines (79).  
 Studies show that supplementation of isomalto-oligosaccharides (IO), 
increases concentrations of bifidobacteria in healthy adults. IOs are oligomers 
that naturally occur in fermented foods such as miso and soy sauce. IOs such as 
isomaltose, isomaltotriose, isomaltotetraose, and panose have α 16 glucosidic 
linkages which resist digestion. IOs act similarly to dietary fiber and are 
fermented by colonic bacteria (77). 
 In a double-blind, placebo controlled study, the effects of IO 
supplementation on fecal microflora, bowel function, and fecal SCFAs in 13 
constipated elderly subjects, resulted in improved bowel function. Subjects 
underwent a run-in period followed by a 4-week period in which they drank a 
placebo drink containing 100mL of water and 4mL of fructose syrup every 
afternoon. For the next 4 weeks (IO1) subjects ingested an IO drink that 
contained 11g IO every afternoon. After the first week of this period, the IO drink 
was increased to 22g a day for the remainder of the time. This treatment was 
repeated for an additional 4-week period (IO2). The IO supplementation period 
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was followed by a 4-week post period. Fecal characteristics and microflora were 
determined from fecal stool samples taken at the last week of each period (78). 
  Results showed that concentrations of bifidobacteria, lactobacilli, 
bacteroides, and total bacteria were significantly increased after IO 
supplementation and remained higher than in the post period compared to the 
placebo period. Fecal bifidobacteria content increased approximately 5%, fecal 
lactobacilli content doubled, and stool output increased 24% from the end of the 
placebo period to the end of the IO2 period. There was an increase in SCFAs in 
the feces following IO supplementation. Acetate concentrations increased 42.6% 
after IO1, 89.2% after the IO2, and remained 32% higher in the post period 
compared to the placebo. Total SCFAs (acetate, propionate, and butyrate) 
increased in both IO periods and remained high in the post period (75.9%, 
134.0%, and 36.1% respectively) compared to the placebo period. This study 
showed that increased fermentation in the colon lead to improved fecal 
microflora, SCFAs, and bowel function, suggesting an improvement in colonic 
health (78). 
Short Chain Fatty Acids and Colonic Health 
 Research shows SCFAs contribute to good colonic health. SCFAs such 
as n-butyrate, propionate, and acetate are produced by colonic fermentation and 
absorbed in the colon through passive transport (80). These fatty acids improve 
colonic health because they promote normal turnover of colon cells (79). SCFAs 
may also help reduce the risk for chronic disease, including type 2 diabetes, by 
improving appetite regulation and inflammatory responses (81). 
 A study conducted by Tarini and Wolever in 2010 found that SCFAs 
reduce concentrations of free-fatty acids and ghrelin, an appetite-regulating 
   29 
hormone. Twelve healthy subjects (age 26+1.8) came in on 3 separate occasions 
following an overnight fast. Subjects consumed a test drink containing either 80g 
high fructose corn syrup, 56g of high fructose corn syrup plus 24 g oliggofibre 
instant inulin, or 56g of high fructose corn syrup dissolved in water (control) with 
a 1-week washout between treatments. A fasting blood sample was taken before 
each test drink and subsequent blood samples were taken at various intervals up 
to 4 hours post ingestion. A lunch consisting of a cheese and tomato sandwich, 
apple juice, water and 2 chocolate cookies was provided after the 4-hour blood 
sample was taken. Additional blood samples were taken after lunch at various 
intervals over the next 2 hours. After the inulin treatment, serum acetate levels 
were 90% higher at 4-6 hours than the other treatments (p<0.05). Propionate and 
butyrate concentrations were 50% higher 4-6 hours after inulin ingestion 
compared to the other treatments (p<0.05). Concentrations of free fatty acids 
(FFAs) decreased with all treatments, but were much lower after the inulin 
treatment at 4 hours compared to the 56g of high fructose corn syrup (-0.11 
mmol/L p<0.05). Serum gastric inhibitory polypeptide (GIP) was significantly 
decreased 30 minutes after the inulin treatment and ghrelin was significantly 
lower at 4.5 and 6 hours (p<0.05). The results from this study suggest that there 
may be a link between SCFAs and reduced concentrations of ghrelin and FFAs. 
The authors allude to the fact that SCFAs produced by colonic fermentation may 
protect against diabetes. They suggest that SCFAs increase insulin sensitivity by 
decreasing concentrations of postprandial FFAs and decrease food intake by 
beneficially influencing appetite-regulating hormones, such as ghrelin (81).  
 Aside from improving appetite regulation, SCFAs may also reduce 
chronic inflammation associated with disease. Chronic inflammation is a result of 
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recruitment and activation of immune cells that release pro-inflammatory 
cytokines into the circulation. These cytokines include interleukins (IL) and TNF-α 
(82). High levels of IL-6 and TNFα have been associated with obesity. Since 
obesity is a major risk factor for prediabetes and type 2 diabetes, circulating 
concentrations of IL-6 and TNFα are a concern (83). 
 In a crossover study, 10 healthy men consumed a meal of white bread 
(105g) or cooked barley kernels (86g dry kernels cooked in 250g water with 1g 
salt) the evening prior to testing. Each meal provided subjects with 50g of 
carbohydrates and was consumed with 250 ml of tap water. The white bread 
contained 2g nondigestible carbohydrates while the barley kernels contained 
15g. Venous blood was collected at -90, -60, -30, -15, and 0 minutes prior to an 
oral glucose tolerance test (OGTT) and breath samples were collected at -120, -
90, -60, -30, -15, and 0 minutes prior to an OGTT. An OGTT was started after the 
0 min measurements and consisted of 55 g glucose in 250 mL water. Blood 
samples were taken every 15 minutes for 2 hours and then every 30 minutes for 
another 2 hours. Plasma IL-6, TNFα, SCFAs, and breath hydrogen were 
measured. The mean postprandial 4-hour IL-6 concentrations were 74% 
(p=0.024) higher and TNFα concentrations were 32% (p=0.008) higher after the 
white bread meal compared to the barley kernel meal. There was no significant 
difference found in plasma acetate and propionate concentrations between 
treatments. However, butyrate was significantly higher 0-2 hours after glucose 
ingestion the morning following the barley meal compared to the white bread 
meal (p=0.041). Breath hydrogen measures were higher 0-2 and 0-4 hours after 
glucose ingestion the morning following the barley evening meal (40.0+6.5 and 
39.5+7.0ppm) compared to the white bread meal (15.2+1.4 and 14.2+1.2) 
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respectively (p<0.05). This suggests that higher consumption of indigestible 
carbohydrates at an evening meal may increase colonic fermentation, which 
increases SCFAs and leads to lower concentrations of proinflammatory cytokines 
in the plasma (84). 
 Tedelind and colleagues showed that SCFAs may decrease inflammatory 
markers. Human neutrophils were stimulated with lipopolysaccharide (LPS) to 
induce the release of inflammatory markers, such as TNF-α, in cell culture. The 
cells were exposed with 30mmol/L concentrations of acetate, propionate, or 
butyrate. Release of TNF-α was decreased 33% by acetate (p<0.01), 67% by 
propionate (p<0.01), and 75% by butyrate (p<0.01). These SCFAs also 
decreased IL-6 protein release in colon organ cultures obtained from mice. 
Organ cultures were treated to induce production of IL-6 and exposed to 
30mmol/L of acetate, propionate, or butyrate. Levels of IL-6 decreased 67% 
when exposed to acetate, 92% when exposed to butyrate, and 83% when 
exposed to propionate (p<0.01). This study shows that SCFAs have the ability to 
decrease release of cytokines, TNF-α and IL-6, in vitro (82). However, these data 
should be considered carefully since the concentrations of SCFAs are higher 
than physiological levels (85). 
 Usami and colleagues showed that acetate, propionate, and butyrate 
decrease TNF-α. Blood samples were collected from five healthy subjects, and 
mononuclear cells were isolated and incubated with various concentrations (0.5 
to 10 mM) of acetate, propionate, and butyrate. Inflammation was induced by 
LPS in a portion of the samples. TNF-α was measured by enzyme-linked 
immunosorbent assay (ELISA). LPS-induced TNF-α secretion was 58% lower 
after exposure to 2mM of butyrate than in the control containing no SCFAs 
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(p<0.01). TNF-α secretions were approximately 44% lower after exposure to 
2mM propionate and 16% lower after exposure to 30mM propionate (p<0.01). A 
dose-dependent decrease was seen in secretion of TNF-α with acetate, with a 
30% decrease after exposure to 5mM acetate (p<0.01). These results suggest 
that acetate, propionate, and butyrate suppress secretion of LPS-induced TNF-α, 
which should result in anti-inflammatory effects (86).  
 Another study investigated the effects of SCFAs on inflammatory markers 
in vitro and in vivo. Neutrophils and monocytes were isolated from human blood 
samples. Cells were incubated overnight with various concentrations of acetate, 
propionate, and butyrate (0, 0.2, 2, and 20nmol/L) in the presence and absence 
of LPS to induce pro-inflammatory markers. Cytokines, and chemokines were 
measured by ELISA. Results showed that SCFAs inhibited production of TNF-α 
and IL-6 induced by LPS in a dose-dependent manner. SCFAs also inhibited 
monocyte chemotactic protein-1 (MCP-1) production in both cells exposed and 
not exposed to LPS. MCP-1 recruits monocytes, which release cytokines, and 
induce inflammation. Therefore, a decrease in MCP-1, TNF-α, and IL-6 would 
decrease inflammation (87).   
 Research shows that SCFAs may have beneficial effects on health by 
regulating inflammatory and appetite responses in the body. These SCFAs can 
be produced from colonic fermentation; however, SCFAs can be produced in the 
body by other means as well. 
 When acetic acid is ingested in the form of vinegar, it does not require 
fermentation to exert its health benefits in the colon. The acetic acid is 
metabolized to acetate, a SCFA that may directly and indirectly contribute to 
overall colonic health (88).  
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 If vinegar increases fermentation in the colon, SCFAs will be produced in 
amounts that are beneficial to overall and colonic health. These health benefits 
may aid in the prevention and possible treatment of chronic disease, specifically 
pre- and type 2 diabetes (86). 
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Chapter 3 
METHODS 
Participants and study design: 
Subject Selection:  
 Subjects were considered eligible for the study if they were nonsmokers, 
> 20 years of age, not taking insulin, had stable medication use, no unresolved 
medical conditions, and were told by their doctor that they were prediabetic. 
Subjects were excluded if they had any known food intolerances (i.e. 
carbohydrate malabsorption or lactose intolerance). Subjects with known food 
intolerances were excluded from this study because some forms of food 
intolerance cause colonic fermentation. The intention was to only include 
subjects who were told by their doctor that they had prediabetes, however, 
recruiting was not robust so recruitment was expanded to adults at risk for type 2 
diabetes.  
Recruitment 
 Prediabetic men and women > 20 years of age were recruited by list 
serves and flyers for participation in this research. List serves were obtained from 
the Arizona State University campus community and local businesses and 
hospitals. Interested parties were directed to Surveymonkey to complete an 
online medical history questionnaire (see appendix B). Those who qualified and 
still expressed interest to participate in the study were contacted and recruited. 
IRB approval and written consent were obtained (see appendices C and D). 
 This study was a 12-week parallel arm randomized control trial examining 
breath hydrogen as a fermentation marker in adults at risk for type 2 diabetes. 
Weight, height, body fat percentage, and waist circumference measurements 
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were taken 1 week prior to the study, 0, 6 and12 weeks. Weight and body fat 
percentage were measured using a Tanita scale. Fasting venous blood samples 
were taken at weeks 6 and 12 to determine glucose and insulin values. Exit 
fasting breath samples were taken at week 12 to measure subject breath 
hydrogen values and participants were also asked to complete a gastrointestinal 
(GI) questionnaire at this visit to determine if they experienced any 
gastrointestinal changes throughout the study (see appendix E). Subjects used 
glucometers to record daily postprandial glycemia throughout the entire 12-week 
study. 
Sample Size:  
 Preliminary studies examining breath hydrogen concentrations in subjects 
with carbohydrate malabsorption provided data for sample size calculations (72, 
74-76). See appendix F. The alpha error level for the outcomes of this study was 
set at 0.05 and the beta error level at 0.2 (a power of 80% that a difference will 
be seen in fermentation markers due to the intervention). A 20% dropout rate 
was anticipated. The estimated sample size was 40. The assumption was made 
that breath hydrogen would increase approximately 33.5+18.1 ppm in the vinegar 
group and would have little to no change in the placebo group (72, 74-76). 
Participants were stratified by gender, age, and body mass prior to group 
assignment. 
Vinegar Treatments:  
 Subjects enrolled in this study were randomly assigned to receive either a 
vinegar drink or a placebo. The vinegar drink (Bragg Apple Cider Vinegar Drink, 
Bragg Live Foods Inc., Santa Barbara, CA) was 16 fluid oz and contained 2 
tablespoons of apple cider vinegar (1.5g acetic acid). The placebo pill (apple 
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cider vinegar pills, General Nutrition Center (GNC) Pittsburgh, PA) contained 
40mg of acetic acid from vinegar. This pill was used as the placebo treatment 
because research has shown that the amount of acetic acid contained in it are 
miniscule and without effect (23). All participants were required to consume 16 oz 
of the vinegar drink or 2 placebo pills every day for 12 weeks.  
 Participant recorded daily pill or vinegar drink consumption on a calendar 
to measure adherence to the prescribed vinegar treatment regimen. Participants 
were emailed once a week to ensure the treatments went as prescribed, ask if 
they had questions about the study, and remind them to mark daily treatment 
completion on their calendars. 
Protocol and Procedures 
 Subjects were screened for inclusion and exclusion criteria through an 
online medical history questionnaire (see appendix B). Those who fit the subject 
criteria were asked to visit the test site one week prior to the start of the trial. 
After visit 1, participants were randomly assigned a treatment. At week 0, 
participants came in for a second visit. At this time they were informed of the 
treatment protocol and provided with the corresponding vinegar drinks or pills 
and glucometers. Subjects also provided written informed consent at this time. 
Baseline measures of height, weight, waist circumference, glucose, and insulin 
were collected at week 0. 
 Participants were asked to record their blood glucose values daily for one 
week prior to starting treatment to collect baseline data. Participants in the 
vinegar drink group were directed to consume 8oz of the vinegar drink prior to 
lunch and dinner, every day, for 12 weeks (16oz total per day). Placebo group 
participants were directed to take 2 placebo pills prior to lunch and dinner with 
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8oz of water, every day for 12 weeks. All participants were asked to maintain 
their usual diet and activity patterns for the duration of the trial. 
Laboratory Analyses 
Breath Hydrogen Measures 
 Three consecutive breath samples were taken from each subject at week 
12 of the study. Hydrogen gas was measured by a hydrogen breath analyzer 
(BreathTracker SC model QTL0054 REV E and QuinTron AlveoSampler bags 
modelQT00842-P, QuinTron, Milwaukee, WI). The investigator used the protocol 
outlined in the AlveoSampler instructions (see appendix G) and the QuinTron 
BreathTracker SC Instrument instructions (see appendix H). 
Blood Glucose and Insulin 
 Fasting blood draws (<1/2 tbsp/day) were taken at weeks 0 and 12. 
Capillary blood glucose was also measured and recorded daily from glucometers 
for one week prior to the start of the trial and for the entire 12-week trial. Each 
subject was assigned a glucometer (ACCU-CHEK, Avia meter system) to 
measure and report daily blood glucose concentrations at 2-hours post-meal 
ingestion. Glucometers were collected from subjects at weeks 6 and 12 to 
download daily glucose measures. The results pertaining to blood glucose and 
insulin data were part of a companion study and will not be reported in this paper. 
Statistical Analyses 
 Anthropometric data, descriptive data, glucose, insulin, and breath 
hydrogen measures were analyzed using SPSS v.19 Statistical Analysis System 
(SAS, Chicago, IL) to run descriptive and inferential statistical analysis. Outcome 
variables were tested for normality. Skewed data was log-transformed for 
analysis. All values are expressed as mean + SEM, unless otherwise indicated. 
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Data change was calculated (week 12 to baseline) and compared using 
independent t-tests for glucose and insulin. If data was normally distributed the 
Pearson correlation was used. A Spearman correlation was run on all non-
normal data. Exit breath hydrogen measures were statistically analyzed using 
univariate analysis. Data was considered statistically significant at p < 0.05. 
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Chapter 4 
RESULTS 
Recruitment 
 A total of 56 people completed the questionnaire on Surveymonkey. Of 
these people, 48 qualified to participate in this study and were solicited. A total of 
23 participants were enrolled in the study. Two people were excluded from the 
study because they were taking diabetic medications to control blood glucose 
and 7 others dropped from the study for various reasons. Of the 7 subjects who 
dropped, two acquired sickness and/or injuries unrelated to the study, two did not 
have enough time to participate, one did not believe sufficient compensation was 
offered, one reported that the vinegar made her nauseous, and one stopped 
responding. It was originally planned to recruit subjects who were told by their 
doctor that they had prediabetes, however, recruiting was not robust so the study 
was expanded to include people at risk for type 2 diabetes and one vegetarian to 
participate in the study.  
Treatment Adherence 
 Participant adherences to prescribed treatments were measured by self-
reported treatment completion on a calendar provided to each participant at the 
beginning of the study. Each treatment was to be taken twice a day and 
participants were to mark completion of these treatments on a calendar each day 
for the entire 12-week study. The participants returned these calendars at the 
duration of the study.  
 Adherence was determined by the percentage of days each participant 
reported taking their treatment 0, 1, or 2 times each day. Individual percentages 
for each group were averaged to give a mean group percentage of the amount of 
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days each participant reported completing their treatment 0, 1, or 2 times each 
day. Three participants from the pill group did not return their adherence 
calendars and were excluded from the analysis of participant adherence. Overall, 
the drink group (n=7) reported that they did not complete any of their treatments 
7% of the days, completed their treatment once a day 4% of the days, and 
completed their treatment twice a day 89% of the days. The pill group (n=4) 
reported that they did not complete any of their treatments 7% of the days, 
completed their treatment once a day 16% of the days, and completed their 
treatment twice a day 77% of the days. See Figure 1. 
 
Figure 1. Comparison of group adherence to prescribed treatment. Each treatment was to be  
taken twice a day. This figure shows a comparison of the adherence reported by each subject  
on his or her daily treatment calendar. Adherence for each particular group is represented as 
a percentage of the amount of days the participants of that particular group reported completing 
their treatment 0, 1, or 2 times a day. Three participants from the Pill Group did not return 
their adherence calendars and were excluded from the analysis shown above.  
Drink Group n=7 and Pill Group n=4. 
 
Descriptive Statistics 
 All statistical tests used to determine outcome and descriptive measures 
were run as non-parametric tests due to the small sample size of the study. Chi-
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Square tests were used to determine the amount of males, females, and 
prediabetics involved in the study. All data was reported as mean+SE and Mann-
Whitney tests were run to compare means of the variables and provide p-values 
for these comparisons.  
 Of the 14 participants that completed the study, 50% were in the drink 
group and the remaining 50% were in the pill group. Only one participant 
involved in the study was male and he was in the pill group. Forty-three percent 
of total participants were told by their doctors that they were pre-diabetic. Of the 
participants in the drink group, 29% were prediabetic and 71% were not. Of the 
participants in the pill group, 57% were prediabetic and 43% were not. There 
were no significant differences in descriptive characteristics of the study 
participants in the drink group and the pill group at baseline. See Table 1.  
Table 1       
Descriptive characteristics of all study participants at baseline (n=14) 
Characteristics 
Drink Group 
(n=7) 
Pill Group 
(n=7) p-value 
Male 0/7  1/7  
Female 7/7  6/7  
Prediabetic  2/7  4/7  
Age (yrs) 48+5 44+6 0.898 
Weight (lbs) 168+14 169+16 0.949 
Body Mass Index (kg/m2) 29+2 28+2 0.655 
% Body Fat 34+5 34+4 0.749 
Waist Circumference (in) 36+2 36+2 0.798 
Venous Fasting Glucose (mg/dL) 101+5 96+6 0.810 
Venous Fasting Insulin (uU/mL) 17+3 21+5 0.873 
HOMA-IR  4+1 5+1  0.910  
All values are represented as mean+SE. All p-values were determined using Mann-
Whitney non-parametric tests. HOMA-IR is the homeostasis model assessment-estimated 
insulin resistance index. HOMA-IR was determined by multiplying fasting glucose 
(mmol/L) by fasting insulin (mU/L) and dividing by 22.5. No significant difference between 
means at the .05 level. 
Fasting BH2 Values 
 Fasting breath hydrogen (BH2) values were log-transformed to normalize 
the data (Shapiro-Wilk test of normality p = 0.058).  Age was correlated to BH2  
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(r = .406).  The univariate analysis was used to examine differences between 
groups using the log of BH2 and controlling for age. The mean fasting BH2 
values were 0.76+0.21ppm for the drink group (n=7) and 0.38+0.16ppm for the 
pill group (n=7) with a partial eta squared of 0.387 (p=0.023). This suggests that 
39% of the BH2 variance can be explained by the vinegar treatment (p=.023). 
 Although logBH2 values were normal, one subject who was considered 
an outlier was excluded from analysis (this subject was a vegetarian and had 
much higher fasting BH2 values compared to the other subjects in the study). 
After removing the outlier, another univariate analysis of logBH2 was run 
controlling for age. With this outlier removed, the mean fasting BH2 values were 
0.57+0.10 for the drink group (n=6) and 0.38+0.16 for the pill group (n=7) with a 
partial eta squared of 0.345 (p=0.045). This shows that 35% of the BH2 variance 
can be explained by the vinegar treatment. The mean fasting BH2 values found 
for the placebo pill group (3.6+1.4) were consistent with fasting BH2 values from 
other studies in healthy controls (89, 90). See Table 2 and Figures 2 and 3. 
Breath methane results were also collected, however, it appeared that most 
participants in this study were not methane producers. See Figure 4. 
Table 2         
Exit fasting breath hydrogen measures of drink group and pill group   
  Drink Group Pill Group Partial Eta Squared p-value 
BH2 (ppm)a 16.1+11.8 3.6+1.4 0.39 0.023* 
BH2 (ppm)b 4.3+1.1 3.6+1.4 0.35 0.045* 
All values are represented in ppm as Mean+SE. BH2 was log transformed to normalize data 
prior to analyses. We controlled for age because it was correlated with BH2 (r=0.406). 
a. All subjects (n=14)    
b. Outlier removed (n=13)    
*Significant difference in mean BH2 values between the drink group and the pill group were 
determined at the .05 level 
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Figure 2. Comparison of the effects of daily vinegar consumption on mean fasting BH2  
measures (ppm) for participants of the drink group (n=6) compared to participants of the  
pill group (n=7). Values represented as Mean+SE. 
 
 
 
Figure 3. Individual fasting BH2 values (ppm) of the drink group (n=6) and the pill group  
(n=7) reported according to age, which correlated with fasting BH2 values (r=0.406). One  
subject in the drink group (age 30) was an outlier with a fasting BH2 of 86.7 ppm and was 
excluded for analysis. 
*Male subject 
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Figure 4. Individual fasting breath methane values (ppm) of the drink group (n=7) and the pill group 
(n=7) reported according to age. 
*Male subject 
 
GI Questionnaire 
 At the duration of the study, all participants filled out a questionnaire that 
reported information about their experiences with the vinegar and its effects on 
their GI system. 
 Six out of seven of the participants in the drink group reported that the 
vinegar source was easy to incorporate into their diet and that they consumed it 
everyday. The remaining participant reported that the vinegar drink was not 
easily incorporated into her diet and she did not consume the vinegar source 
daily because it made her nauseous. All participants of the vinegar pill group 
reported that the vinegar source was easy to incorporate into their diet and they 
consumed their vinegar source daily. Three of seven of participants in the 
vinegar group and Three of seven participants in the drink group reported that 
they consumed other vinegar containing foods during the study (salad dressing 
and pickles). Four of seven participants in the vinegar group and four of seven 
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participants in the drink group reported that they did not consume vinegar from 
any additional sources.  
 Participants were asked if they experienced any change in flatulence, 
stool frequency stool consistency, or bloating during the study. If participants 
reported a change in any of these areas, they rated that change on a scale of 1-5 
with 1 being “little change” and 5 being “a lot of change.” None of the participants 
in the pill group reported a change in flatulence and 5 out of 7 participants in the 
drink group reported no change in flatulence. The remaining 2 participants in the 
drink group reported a 2.5 average change in flatulence. Six out of 7 of the drink 
group participants reported no change in stool frequency while the remaining 
participant reported a change in stool frequency which she rated a change of 2. 
The pill group also reported that 6 out of 7 participants reported no change in 
stool frequency. However, the participant from the pill that reported a change in 
stool frequency rated her change as a 4. All participants in the drink group and 6 
out of 7 participants from the pill group reported no change in stool consistency 
throughout the study. The participant from the pill group that reported a change in 
stool consistency rated her change as a 1 and reported that her stool was more 
firm. Six out of 7 of the drink group participants reported no change in feelings of 
bloating and 1 participant reported feelings of bloating which she rated a 2. Five 
of 7 participants in the pill group reported no change in feelings of bloating and 2 
participants reported a change in feelings of bloating with an average rated 
change of 2.5. 
 When asked if any of these symptoms interfered with normal daily 
activities, only 1 of 14 total participants said yes with nausea as her chief 
complaint. Participants were also asked if any of these symptoms made them 
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change or avoid any social activities during the study and all reported normal 
social activities. See Table 3. 
Table 3         
Summary of participant responses to questions asked in the GI questionnaire (n=14). 
  Drink Group Pill Group 
Question Yes % Yes % 
Was the vinegar source easy to incorporate into your diet?  6/7 86% 7/7 100% 
Have you eaten any vinegar sources other than treatment?        3/7 43%  3/7 43% 
Have you experienced changes in flatulence (gas) frequency?  2/7 29%  1/7 14% 
Have you experienced any changes in stool frequency?   1/7 14%  1/7 14% 
Have you experienced any changes in stool consistency? 0/7 0%  1/7 14% 
Have you felt bloating since the beginning of the study?  1/7 14%  2/7 29% 
Have symptoms interfered with your normal daily activities?  1/7 14% 0/7 0% 
Have symptoms made you change any social activities?  0/7 0% 0/7 0% 
Complete questions are represented in the GI Questionnaire in the appendix. For the drink group 
n=7 and for the pill group n=7. All participant responses are represented as ratios and 
percentages of the treatment group to which they belong. 
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Chapter 5 
DISCUSSION 
 People with prediabetes and type 2 diabetes often find it difficult to keep 
fasting and postprandial blood glucose levels within normal ranges (fasting blood 
glucose, 80-110 mg/dl and postprandial blood glucose 120-140 mg/dl), therefore, 
various suggestions of methods to help control blood glucose levels and prevent 
or delay the onset of type 2 diabetes are consistently found in the literature (6-8). 
Among these methods, the ingestion of vinegar prior to mealtime has been 
shown to decrease postprandial glycemia in healthy subjects, prediabetics, and 
type 2 diabetics (17-20, 22-24, 54, 55). Additional research has been conducted 
to explore the mechanisms of vinegar action; however, the mechanism(s) remain 
obscure (20, 24, 56, 59, 63, 65-67). Therefore, this study examined a potential 
mechanism for the antiglycemic property of vinegar, namely the effect of vinegar 
ingestion on gut fermentation. This was explored to ascertain whether vinegar 
increased fermentation markers, which would indicate an increase in gut 
fermentation itself. An increase in gut fermentation would support the notion that 
vinegar inhibits the digestion of starch in the small intestine. 
 In this randomized, placebo-controlled trial, subjects consumed 16 oz of a 
vinegar drink (1.5 g acetic acid) everyday or a placebo (2 vinegar pills containing 
40 mg acetic acid each) everyday for 12-weeks. Subjects consumed 8 oz (1 
tablespoon of vinegar) of the vinegar drink or one vinegar pill (40 mg acetic acid) 
immediately prior to lunch and dinner meals. Subjects filled out a GI 
Questionnaire and BH2 was measured from fasting breath samples collected at 
week 12 of the study. 
 
   48 
Breath Hydrogen 
 After controlling for age as a confounding factor (r=0.406), and removing 
an outlier, fasting BH2 measures for the vinegar drink group were significantly 
greater than those for the pill group (4.3+1.1 ppm and 3.6+1.4 ppm respectively) 
with a partial eta squared of 0.35 (p=0.045). Thus, 35% of the variance in fasting 
BH2 values could be attributed to the vinegar treatment. According to these 
results it appears that those who consume vinegar daily may have higher fasting 
BH2 values compared to those who do not. It is possible that the vinegar may 
inhibit the digestion of starch in the small intestine, causing it to pass into the 
colon and increase fermentation, which would ultimately raise BH2 values. A rise 
in BH2 values should indicate an increase in fermentation because once 
hydrogen, a major end product of fermentation, is produced in the colon, it 
diffuses into the blood, and is exchanged into the breath. This hydrogen is 
excreted in the breath where it can be measured as a marker of colonic 
fermentation (71). 
 Studies suggest that undigested and/or partially digested carbohydrates 
that pass into the colon are broken down further by fermentation. In a crossover 
trial of 10 healthy volunteers, subjects consumed breakfasts consisting of various 
amounts of indigestible carbohydrates on three separate occasions in random 
order followed by a standard meal five hours after breakfast. BH2 was measured 
every 30 minutes for 2 hours after breakfast, then every hour until lunch. After 
lunch, BH2 was measured every 30 minutes for 2 hours and then every hour until 
the total study had reached 10 hours. BH2 was significantly higher in subjects 
after they consumed the meals that were higher in indigestible carbohydrates 
(p<0.001). The average peak breath hydrogen concentration at 7 hours (2 hours 
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after lunch) was 18 ppm after consuming a low glycemic index meal and 26 ppm 
after consuming a high glycemic index meal with lactulose, a highly fermentable 
and indigestible disaccharide. This suggests that the indigestible carbohydrates 
passed into the colon where they were broken down by fermentation (75). 
Another study that explored indigestible carbohydrate content of foods measured 
BH2 to determine the amount of fermentation that took place in the colon after 
consumption of these indigestible carbohydrates. The largest difference in 
postprandial BH2 was found between the consumption of white bread (17.2+2.6 
ppm) and barley kernels that are high in dietary fiber (41.0+5.1 ppm) (p<0.001). 
These results suggest that BH2 values will be higher after the consumption of 
foods containing high amounts of indigestible carbohydrates (76),  
These studies show that as indigestible carbohydrate sources pass into 
the colon, colonic fermentation increases resulting in an increased production of 
hydrogen gas that diffuses into the blood, and is excreted in the breath where it 
can be measured (71, 75). Therefore, since this study observed a significantly 
higher fasting BH2 measure in the vinegar group compared to the placebo pill 
group, it is possible that this was observed because the vinegar caused 
undigested starch to pass into the colon, where it was fermented, leading to 
increased presence of hydrogen gas in the breath. It is expected that acute 
testing for postprandial BH2 values may show a greater difference in BH2 after 
consumption of a vinegar test meal compared to a control. This would provide 
additional data to determine if vinegar is responsible for a rise in BH2. Therefore, 
future studies should examine the acute effect of vinegar on BH2 to further 
explore this link between vinegar and the presence of hydrogen in the breath. 
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Validity and Reliability 
 The investigator measuring breath samples attended a training meeting 
with the staff at QuinTron to learn how to appropriately obtain the samples and 
use the BreathTracker SC digital microlyzer to ensure measurement validity of 
BH2.  When the breath samples were collected, all subjects were asked to take a 
normal breath, breathing in through his or her nose and out through his or her 
mouth for the breath sample collection. Definition of a normal breath can be 
subjective, so subjects were observed for signs of abnormal breathing such as 
gasping or wheezing sounds, forced inspiration or expiration, lifting of the 
shoulders to expand the rib cage and fill the lungs, or subjective chest expansion. 
To ensure subjects took a normal breath to collect the breath sample, all 
participants were asked to focus on their normal breathing prior to collection of 
the breath sample. They were also asked to take a practice breath into the breath 
collection bag and were observed for signs of abnormal breathing as described 
above. If subjects appeared to exhibit any of these signs they were asked to take 
another breath for collection.  Following these procedures, the fasting BH2 
measures of the placebo control group (3.6+1.4 ppm) were consistent with those 
found in other studies, which showed fasting BH2 measures in healthy controls to 
be about 3-4 ppm (89, 90). 
 Reliability was also carefully assessed during BH2 measurements.  Three 
consecutive breath samples were taken from each subject for BH2 
measurement. The three BH2 measures were averaged for the recorded value. 
The intraclass correlation coefficient (ICC=0.946) showed that these measures 
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were strongly correlated (p<0.001). This analysis indicates that the BH2 
measures from the breath samples were consistent and reliable. 
GI Questionnaire 
 GI symptoms, such as increased gas production, are associated with 
colonic fermentation (73). Because of this, subjects filled out a questionnaire at 
the end of the study to report changes in GI symptoms such as flatulence 
frequency, stool frequency, and stool consistency. It was expected that those in 
the vinegar group would experience more potential changes in GI symptoms 
related to increased fermentation than those in the placebo pill group. However, 
participants in both groups reported mild changes in GI symptoms. Because of 
this, it does not appear that those in the vinegar group experienced any more GI 
symptoms than those in the pill group. Since most subjects in the drink group and 
the placebo pill group did not report much change in these areas, it cannot be 
determined whether or not these data support the assumption that vinegar 
consumption inhibits the digestion of starch in the small intestine to increase gut 
fermentation. However, the sample size for this study is small and changes may 
not have been noticeable or present with this amount of vinegar ingestion. 
Results may appear to be more notable with a larger sample size, more frequent 
measures of subject GI status, or an increased ingestion of vinegar. It is 
suggested that future studies collect data on a larger sample and consider the 
use of a daily log of GI symptoms to better track and report the GI status of each 
subject. It is also possible that the amount of vinegar ingested in this study does 
not have a large enough effect on gut fermentation to cause noteworthy changes 
in GI symptoms.  
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Limitations 
 A small sample size was used in this study, therefore it is suggested that 
larger studies are done to explore this phenomena and produce more robust 
results. It would also be beneficial to conduct short-term studies that measure 
fasting BH2 values before and after a meal at various time intervals as other 
researchers studying BH2 and carbohydrate malabsorption have done (75, 76). 
Studies may also consider using a tool to measure GI symptoms more frequently 
and more closely. 
 The breath microlyzer used to run the breath samples in this study 
reported both BH2 and breath methane values for each sample. No relationship 
was found between vinegar ingestion and breath methane. Mean BH2 and 
breath methane values were not correlated. It would be beneficial for future 
studies to measure other more sensitive markers of fermentation in addition to 
BH2 and breath methane with closer monitoring of GI symptoms to report better 
construct validity. This would give stronger data to support whether or not vinegar 
ingestion increases colonic fermentation. 
 It does not appear that there is a gold standard against which to compare 
BH2 measures (91). In fact, it appears that BH2 is the most sensitive and 
commonly used measure of colonic fermentation in the literature (72, 74-76, 91-
93). 
 BH2 is considered the most promising measure for evaluating colonic 
fermentation because the method is non-invasive and highly sensitive (92, 94). 
No known mammalian cell produces hydrogen and methane. The formation of 
these gases is specific to anaerobic bacteria, which are found in the flora in the 
colon (94-97). Therefore, the presence of hydrogen and methane in the breath 
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should be a valid and specific indicator of colonic fermentation (96, 98). BH2 is 
considered a sensitive measure of fermentation, however, recent research 
indicates that methane may not be. These findings indicate that some people are 
naturally methane producers or non-producers, therefore, breath methane is not 
very sensitive measure of actual colonic fermentation (72, 92-94). The literature 
states that CO2 produced from colonic fermentation of starch is converted to 
methane by methanogenic bacteria in the colon. This methane diffuses into the 
blood, then into the breath where it is excreted. The measurement of breath 
methane is not considered a very sensitive marker of fermentation because 
methanogenic bacteria are only present in about 50% of the population. Those 
who carry methanogenic bacteria are considered methane producers. Those who 
do not are considered non-producers (70). Breath hydrogen and methane 
measures can be affected by the presence or absence of hydrogen and methane 
producing flora in the gut. Gut flora may be altered by various practices, such as 
the use of antibiotics (98). Despite this, BH2 is still considered the most 
promising measure of gut fermentation (92, 94). 
 Subject reported GI symptoms such as discomfort related to flatulence 
and bloating can serve as a measure for fermentation as the production of gases 
from the fermentation process can result in these symptoms (99, 100). For 
example, fermentable fibers lead to increased gas production, flatus frequency, 
and feelings of bloating in human subjects (99, 101). Since GI symptoms are 
self-reported and can be related to other health and medical conditions, such as 
irritable bowel syndrome, these symptoms are not a good measure of 
fermentation alone. However, they can serve as a good indicator of colonic 
fermentation in combination with other measures (101). 
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 The intention for this study was to complete pre and post measures of 
fasting BH2 values for both the vinegar group and the placebo pill group to 
determine any changes in fasting BH2 values, however, instrumentation was not 
obtained in time to do a pre and post measure. Because of this an exit fasting 
BH2 measure was conducted. One might argue that a pretest is not necessary 
for this type of design as the purpose of a pretest is to determine if groups are 
different prior to treatment and subjects for this study were stratified and 
randomly assigned to groups. Using this type of research design, the goal is to 
determine if the dietary intervention caused a significant change in 2 randomized 
and largely similar (p>0.05) groups at the end of the treatment period (102).  
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Chapter 6 
CONCLUSION 
 Data from this research suggests that daily consumption of vinegar may 
lead to higher fasting BH2 values in individuals at risk for type 2 diabetes. 
Increased BH2 values are an indicator of increased colonic fermentation, which 
suggests that vinegar ingestion may increase fermentation in the colon. This may 
explain why vinegar consumption prior to mealtime is linked to decreased 
postprandial glycemia (17-20, 22-24, 54, 55). This was the first study to explore 
the effects of vinegar ingestion on colonic fermentation measuring fasting BH2.  
 These results may not be completely representative of the population at 
large because a small sample size (n=14) was used, only post BH2 measures 
were taken, and not all markers of fermentation measured were considered 
sensitive. Additional research is needed to determine if vinegar increases colonic 
fermentation by measuring long-term and acute BH2 and breath methane values 
and tracking daily GI symptoms. Future studies should use a larger sample size 
and explore these effects in various independent populations such as healthy, 
prediabetic, and type 2 diabetic subjects. Short-term studies exploring the effects 
of vinegar on colonic fermentation, specifically breath hydrogen measures would 
help to further explore these effects as well. It is suggested that short-term 
studies measure fasting BH2 values and postprandial BH2 values following a 
vinegar test meal in several time increments. Past studies observing BH2 as a 
byproduct of fermentation collected measures in 30-minute increments for 2 or 
more hours post meal ingestion (75, 76). Future research in this area may lead to 
additional information about how vinegar works to decrease postprandial 
glycemia. 
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QUINTRON ALVEOSAMPLER INSTRUCTIONS 
 
The QuinTron AlveoSampler is a disposable tool that consists of a collection 
bag, a mouthpiece with an opening to connect a syringe, and a syringe with a 
stopcock and pull plunger to collect alveolar air. This tool is only meant to be 
used on a single patient, then discarded to eliminate risks associated with breath 
sample contamination and inter-patient cross-infection. 
 
AlveoSampler Assembly 
1. Remove bag, mouthpiece, and syringe from sealed bag. 
2. Put the stopcock on the syringe and open it. 
3. Attach the syringe to the AlveoSampler bag by placing the male end of 
the stopcock into the opening in the side of the plastic mouthpiece. 
 
Breath Sample Collection 
1. Have the patient take a normal breath and place the mouthpiece into the 
mouth at the end of inspiration with his/her lips closed tightly around it. 
Instruct the patient to exhale normally into the bag so it fills with air. The 
bag is vented with a small hole to allow the patient to maintain exhalation. 
2. Collect 20 ml of alveolar air in the syringe by pulling the plunger out of the 
syringe while the bag is inflated and the patient is exhaling into the bag.  
3. Once 20 ml has been collected, close the stopcock on the syringe to 
collect the sample. At this point, the patient can stop exhaling and remove 
the mouthpiece. 
4. Remove the syringe filled with the sample from the mouthpiece and 
analyze the sample within 2 hours. If the sample needs to be held for a 
longer time a sample holding bag can be obtained. 
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QUINTRON BREATHTRACKER INSTRUCTIONS 
Instrument Warm up 
 
Turn on the main power and the pump power. Allow the BreathTracker to warm-
up for at least 48 hours before calibrating the machine or analyzing the samples. 
If the BreathTracker is on standby (main power on and pump power off), allow at 
least 8 hours for warm-up prior to calibration. 
 
Instrument Calibration 
 
1. The display should read 0 for each gas, if not, push the ZERO (Ø) key. 
2. Perform the full calibration. Collect >20 ml QuinGas in the 
calibrationsyringe and close stopcock. Insert syringe into the sample port 
on the BreathTracker, open the stopcock, and inject > 20 ml QuinGas. 
Press the START key. 
3. Then, perform the half calibration. Collect 15 ml QuinGas and 15 ml 
room air in the calibration syringe and close the stopcock. Insert syringe 
into the sample port on the BreathTracker, open the stopcock, and inject 
the diluted QuinGas. Press the START key. 
4. The display will read CAL DONE when the calibration is complete. 
 
Note: Calibration may required again depending on the length of the testing     
          session QuinTron recommends at least two calibrations if analyzing     
          patients over an eight hour time period. 
 
Sample Analysis 
 
1. Review the breathing technique and instructions for breath sample 
collection with the patient. 
2. Collect the patient sample using the collection tool (bag, mouthpiece, and 
syringe) as outlined in the AlveoSampler instructions. 
3. The display should read 0 for each gas, if not, push the ZERO (Ø) key. 
4. Insert the sample drying tube into the sample port of the BreathTracker. 
5. Attach the syringe containing the patient sample to the sample drying 
tube, turn the stopcock, and inject > 20 ml of the patient sample into the 
sample drying tube. Press the START key. 
6. Once the sample has been analyzed use the self-correction feature by 
pressing the DOWN key. The corrected H2 and CH4 values should 
appear on the display with a correction factor. 
7. If the correction factor is above 4.0, the sample is contaminated and 
another sample should be collected and analyzed to replace the 
contaminated sample. If the correction factor is below 4.0, record all 
values (H2, CH4, CO2, and the correction factor). 
8. Press the START key and wait for the LED status light to blink green to 
run the next sample. 
. 
